The Latent TB Detection Market is developing as demand increases for reliable methods of detecting tuberculosis infection without waiting for active disease symptoms. The market reached USD 7.09 billion in 2024 and is forecast to reach USD 12 billion by 2032, with a 6.8% CAGR.

Healthcare technology is shifting toward faster and more convenient diagnostic methods. T-SPOT.TB, QuantiFERON-TB Gold, IGRA testing, molecular diagnostics, and automated immunoassays are among the technologies shaping the market.

Diagnostic services form a major application area, while screening is also expected to expand. Hospitals account for the largest end-user segment, with clinics and diagnostic centers contributing to wider testing availability.

North America remains the leading regional market, supported by advanced healthcare facilities and established diagnostic networks. Europe has steady demand, while Asia-Pacific offers considerable growth potential due to increasing healthcare investment and TB awareness.

The next stage of development may focus on point-of-care devices, faster molecular tests, AI-assisted interpretation, and affordable screening platforms. These solutions could help improve the reach and efficiency of latent TB detection.